Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials

Autor:	Frank A. Post, Cynthia Brinson, Debbie Hagins, Hans-Jürgen Stellbrink, Claudia Martorell, B. Rashbaum, Morales-Ramirez J, H Liu, Chloe Orkin, Eric S. Daar, Y P Liu, Das M, Melanie A. Thompson, Sean E Collins, Devi SenGupta, Anthony Mills, Olayemi Osiyemi, Edwin DeJesus, Danielle Porter
Rok vydání:	2018
Předmět:	Adult Male 0301 basic medicine medicine.medical_specialty Efavirenz Urology HIV Infections Bioequivalence Emtricitabine Tenofovir alafenamide law.invention rilpivirine 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Double-Blind Method renal disease Randomized controlled trial law Antiretroviral Therapy Highly Active Humans Medicine tenofovir alafenamide Pharmacology (medical) 030212 general & internal medicine Original Research Drug Substitution business.industry Health Policy HIV Middle Aged Viral Load 030112 virology Drug Combinations Regimen Treatment Outcome Infectious Diseases Anti-Retroviral Agents chemistry Tolerability Rilpivirine HIV-1 RNA Viral Female bone mineral density business medicine.drug
Zdroj:	HIV Medicine
ISSN:	1464-2662
Popis:	Objectives The single‐tablet regimen rilpivirine, emtricitabine and tenofovir alafenamide (RPV/FTC/TAF) for treatment of HIV‐1‐infected adults was approved based on bioequivalence. We assessed the clinical efficacy, safety and tolerability of switching to RPV/FTC/TAF from either RPV/FTC/tenofovir disoproxil fumarate (TDF) or efavirenz (EFV)/FTC/TDF. Methods We conducted two distinct randomized, double‐blind, active‐controlled, noninferiority trials in participants taking RPV/FTC/TDF (Study 1216) and EFV/FTC/TDF (Study 1160). Each study randomized virologically suppressed (HIV‐1 RNA
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::138e2488e58a22ac23afae9a3c413ba6 https://doi.org/10.1111/hiv.12664 Zobrazit plný text záznamu Plný text ve formátu PDF